Gallia GL et al., 2020-11-12: Single-center phase 1 dose-escalation study of mebendazole plus temozolomide in 24 adults with newly diagnosed high-grade glioma. It reports acceptable toxicity up to 200 mg/kg/day and a median overall survival of 21 months.
Kaplan-Meier analysis showed a 21-month median overall survival with 41.7% of patients alive at 2 years and 25% at 3 and 4 years.
n/a
Gallia GL et al., 2020-11-12: Single-center phase 1 dose-escalation study of mebendazole plus temozolomide in 24 adults with newly diagnosed high-grade glioma. It reports acceptable toxicity up to 200 mg/kg/day and a median overall survival of 21 months. Study type: phase 1, single-arm dose escalation. N=24 (18 glioblastoma, 6 anaplastic glioma). Country: United States (Johns Hopkins). Dose: oral mebendazole 25, 50, 100 and 200 mg/kg/day with adjuvant temozolomide after chemoradiation; 15 patients at 200 mg/kg/day. Funder: Accelerate Brain Cancer Cure, NIH R01CA190223, Cures within Reach, and family gifts. Conflicts: G.J.R. founder of and equity in Benizole Therapeutics; H.B. research funding from Acuity Bio and consultancy/equity in several device companies. Maker: mebendazole supplied/manufactured with Accelerate Brain Cancer Cure support; specific manufacturer not stated in the abstract. Comparator: none (single arm); survival compared informally with historical data. Results: grade 3 ALT/AST in 4 patients at 200 mg/kg, reversible; median PFS 13.1 months in 17 patients on >1 month of mebendazole. Published online 2020-11-12; journal issue 2021;3(1):vdaa154. Also filed as MBB-70, MBD-11 (claims C2, C3, C7).
